GlassScriptPhysician profile
Ashish Sangal
NPI 1043541576
$10,585.88
in general payments reported to CMS, 2019-2025
65 companies · $3,078 in 2025
The $3,078 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $2,814 · 2021: $2,739 · 2022: $665 · 2023: $500 · 2024: $595 · 2025: $3,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,452 · Consulting Fee: $1,675 · Education: $45.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,451.87 |
| Consulting Fee | $1,675.00 |
| Education | $45.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,979.26 | 2020-2025 | Imfinzi, Enhertu |
| Janssen Biotech, INC. | $225.16 | 2019-2025 | Talvey, Darzalex, Tecvayli |
| Merck Sharp & Dohme LLC | $208.72 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $168.16 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $167.77 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $153.65 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $146.96 | 2021-2025 | Ultomiris |
| Amgen INC. | $134.93 | 2019-2024 | Lumakras |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.64 | 2020-2025 | |
| Verastem, INC. | $119.44 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $115.32 | 2021-2025 | Libtayo |
| Lilly USA, LLC | $91.80 | 2021 | |
| Incyte Corporation | $91.02 | 2021-2025 | Monjuvi, Zynyz, Pemazyre |
| Blueprint Medicines Corporation | $89.69 | 2021-2025 | Ayvakit |
| Puma Biotechnology, INC. | $88.26 | 2024-2025 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $82.07 | 2022-2025 | Enhertu, Injectafer |
| Ipsen Biopharmaceuticals, INC | $81.07 | 2021-2025 | Onivyde |
| Gilead Sciences, INC. | $78.02 | 2023-2025 | Trodelvy |
| Eisai INC. | $74.42 | 2021-2024 | |
| Genentech USA, INC. | $70.07 | 2024-2025 | Itovebi, Tecentriq Hybreza, Tecentriq |
| Kyowa Kirin, INC. | $69.47 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.56 | 2023-2025 | Fruzaqla, Vpriv, Ninlaro |
| Dendreon Pharmaceuticals LLC | $66.10 | 2021-2022 | |
| Epizyme, INC. | $66.02 | 2021-2022 | |
| G1 Therapeutics, INC. | $62.38 | 2022-2023 | Cosela |
| E.R. Squibb & Sons, L.L.C. | $56.87 | 2022 | |
| Mirati Therapeutics, INC. | $49.43 | 2023-2024 | Krazati |
| Stemline Therapeutics INC. | $41.35 | 2023-2025 | Orserdu |
| Springworks Therapeutics, INC. | $40.57 | 2024 | Ogsiveo |
| Genmab U.S., INC. | $40.36 | 2025 | Tivdak |
| Galvanize Therapeutics, INC | $40.00 | 2025 | Aliya System |
| Janssen Pharmaceuticals, INC | $37.83 | 2022-2023 | Xarelto |
| Beigene USA, INC. | $36.30 | 2021-2023 | Brukinsa |
| Amag Pharmaceuticals, INC. | $34.83 | 2021-2022 | |
| Novocure INC. | $32.81 | 2025 | Optune Lua (Novottf-200t) |
| Astellas Pharma US INC | $32.45 | 2024 | Xospata |
| Acrotech Biopharma INC. | $32.13 | 2024 | Beleodaq |
| Pfizer INC. | $29.99 | 2023 | |
| Abbvie INC. | $27.96 | 2024 | |
| Nuvation Bio INC. | $27.67 | 2025 | Ibtrozi |
| Sobi, INC | $25.73 | 2024 | |
| Ge Healthcare | $25.45 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $23.30 | 2021 | |
| Karyopharm Therapeutics INC. | $23.06 | 2025 | Xpovio |
| Agios Pharmaceuticals, INC. | $22.95 | 2025 | Pyrukynd |
| Ethicon US, LLC | $22.61 | 2021 | |
| Glaxosmithkline, LLC. | $21.87 | 2024 | Zejula, Jemperli |
| Menarini Silicon Biosystems, INC. | $21.87 | 2023 | Cellsearch |
| Boston Scientific Corporation | $21.72 | 2025 | Bulkamid |
| Celgene Corporation | $20.73 | 2021 | |
| Pharmacosmos Therapeutics INC. | $20.22 | 2024 | Monoferric |
| Legend Biotech USA INC. | $20.05 | 2025 | Carvykti |
| Azurity Pharmaceuticals, INC. | $19.81 | 2025 | Danziten |
| Eusa Pharma (US) LLC | $18.61 | 2022 | |
| Deciphera Pharmaceuticals INC. | $18.59 | 2025 | Qinlock, Romvimza |
| Pharmaessentia USA Corporation | $16.93 | 2025 | Besremi |
| Shield Therapeutics INC | $16.63 | 2025 | |
| Seagen INC. | $16.39 | 2022 | |
| Tolmar, INC. | $15.15 | 2025 | Eligard |
| Curium US LLC | $13.70 | 2022 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Sangal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.